Research progress on BRAF gene abnormality in glioma

doi:10.3969/j.issn.1006-7795.2020.03.012

Abstract

Abstract: The serine threonine kinase v-RAF murine sarcoma viral oncogene homologue B1 (BRAF) is a member of the growth signal transduction protein kinase RAF gene family, which regulates mitogen-activated protein kinase/extracellular signal-related kinase pathways and plays an important role in cell division, differentiation and development. BRAF alteration mostly includes BRAF gene mutation and fusion. In recent years, alterations in BRAF are detected in a variety of glioma types. As a unique molecular genetic feature, BRAF alterations provide an important basis for the diagnosis, prognosis and treatment of glioma. This article reviewed the abnormal forms, mechanism and detection of BRAF gene, as well as the role of BRAF alteration in the diagnosis and treatment of glioma.

Key words: glioma, BRAF V600E mutation, KIAA1549-BRAF fusion, BRAF inhibitor

CLC Number:

R739.41

Sun Mengxue, Wang Leiming, Teng Lianghong. Research progress on BRAF gene abnormality in glioma[J]. Journal of Capital Medical University, 2020, 41(3): 380-384.

References

[1] Ostrom Q T, Gittleman H, Liao P, et al. CBTRUS statistical report:primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014[J]. Neuro Oncol, 2017, 19(suppl_5):v1-v88.
[2] Chhabda S, Carney O, D'Arco F, et al. The 2016 World Health Organization Classification of tumours of the Central Nervous System:what the paediatric neuroradiologist needs to know[J]. Quant Imaging Med Surg, 2016, 6(5):486-489.
[3] Hall R D, Kudchadkar R R. BRAF mutations:signaling, epidemiology, and clinical experience in multiple malignancies[J]. Cancer Control, 2014, 21(3):221-230.
[4] Jones D T W, Kocialkowski S, Liu L, et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas[J]. Cancer Res, 2008, 68(21):8673-8677.
[5] Maurer G, Tarkowski B, Baccarini M. Raf kinases in cancer-roles and therapeutic opportunities[J]. Oncogene, 2011, 30(32):3477-3488.
[6] Tomić T T, Olausson J, Wilzén A, et al. A new GTF2I-BRAF fusion mediating MAPK pathway activation in pilocytic astrocytoma[J]. Plos One, 2017, 12(4):e0175638.
[7] Cin H, Meyer C, Herr R, et al. Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma[J]. Acta Neuropathol, 2011, 121(6):763-774.
[8] Shin C H, Grossmann A H, Holmen S L, et al. The BRAF kinase domain promotes the development of gliomas in vivo[J]. Genes cancer, 2015, 6(1-2):9-18.
[9] Schindler G, Capper D, Meyer J, et al. Analysis ofBRAFV600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma[J]. Acta Neuropathol, 2011, 121(3):397-405.
[10] Kleinschmidt-DeMasters B K, Aisner D L,Birks D K,et al. Epithelioid GBMs show a high percentage of BRAF V600E mutation[J]. Am J Surg Pathol, 2013, 37(5):685-698.
[11] Wang J M, Liu Z X, Cui Y, et al. Evaluation of EZH2 expression, BRAF, V600E mutation, and CDKN2A/B, deletions in epithelioid glioblastoma and anaplastic pleomorphic xanthoastrocytoma[J]. J Neurooncol, 2019144(1):137-146.
[12] Tanaka S, Nakada M, Nobusawa S, et al. Epithelioid glioblastoma arising from pleomorphic xanthoastrocytoma with the BRAF V600E mutation[J]. Brain Tumor Pathol, 2014, 31(3):172-176.
[13] Cicuendez M, Martinez-Saez E, Martinez-Ricarte F, et al. Combined pleomorphic xanthoastrocytoma-ganglioglioma with BRAF V600E mutation:case report[J]. J Neurosurg Pediatr, 2016, 18(1):53-57.
[14] 王雷明, 付永娟, 李卓, 等. 存在BRAF V600E突变的混合性多形性黄色星形细胞瘤和节细胞胶质瘤[J]. 中国现代神经疾病杂志, 2017,17(3), 202-208.
[15] Murakami C,Yammazaki T,Shintoku R, et al. Anaplastic ganglioglioma with epithelioid cell components[J]. Neuropathology, 2018, 38(5):498-502.
[16] Lohkamp L N, Schinz M, Gehlhaar C, et al. MGMT promoter methylation and BRAF V600E mutations are helpful markers to discriminate pleomorphic xanthoastrocytoma from giant cell glioblastoma[J]. Plos One, 2016, 11(6):e0156422.
[17] Chen X, Pan C, Zhang P, et al. BRAF V600E mutation is a significant prognosticator of the tumour regrowth rate in brainstem gangliogliomas[J]. J Clin Neurosci, 2017, 46:50-57.
[18] Ho C Y, Mobley B C, Gordish-Dressman H, et al. A clinicopathologic study of diencephalic pediatric low-grade gliomas withBRAFV600 mutation[J]. Acta Neuropathol, 2015, 130(4):575-585.
[19] Nakano Y,Yamasaki K,Sakamoto H,et al. A long-term survivor of pediatric midline glioma with H3F3A K27M and BRAF V600E double mutations.[J].Brain Tumor Pathol, 2019, 36(4):162-168.
[20] Wong D J, Ribas A. Targeted therapy for melanoma[J]. Cancer Treat Res, 2016, 167:251-262.
[21] Kaley T,Touat M, Subbiah V, et al. BRAF inhibition in BRAF-mutant gliomas:results from the VE-BASKET study[J]. J Clin Oncol, 2018,36(35):3477-3484.
[22] Ceccon G, Werner J M,Dunkl V, et al. Dabrafenib treatment in a patient with an epithelioid glioblastoma and BRAF V600E mutation[J]. Int J Mol Sci, 2018, 19(4):E1090.
[23] Brown N F, Carter T, Kitchen N, et al. Dabrafenib and trametinib in BRAFV600E mutated glioma[J]. Cns Oncol, 2017, 6(4):291-296.
[24] Kurani H, Gurav M, Shetty O, et al. Pilocytic astrocytomas:BRAFV600E and BRAF fusion expression patterns in pediatric and adult age groups[J]. Childs Nerv Syst, 2019, 35(9):1525-1536.
[25] Hawkins C, Walker E, Mohamed N, et al. BRAF-KIAA1549 fusion predicts better clinical outcome in pediatric low-grade astrocytoma[J]. Clin Cancer Res, 2011, 17(14):4790-4798.
[26] Dimitriadis E, Alexiou G A, Tsotsou P, et al. BRAF alterations in pediatric low grade gliomas and mixed neuronal-glial tumors[J]. J Neurooncol,2013, 113(3):353-358.
[27] Lawson A R J, Tatevossian R G, Phipps K P, et al. RAF gene fusions are specific to pilocytic astrocytoma in a broad paediatric brain tumour cohort[J]. Acta Neuropathol, 2010, 120(2):271-273.
[28] Yamashita S, Takeshima H,Matsumoto F,et al. Detection of the KIAA1549-BRAF fusion gene in cells forming microvascular proliferations in pilocytic astrocytoma[J]. PLoS ONE, 2019, 14(7):e0220146.
[29] Sievert A J, Lang S S, Boucher K L, et al. Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas[J]. Proc Natl Acad Sci U S A, 2013, 110(15):5957-5962.
[30] Jain P, Silva A, Han H J, et al. Overcoming resistance to single-agent therapy for oncogenic BRAF gene fusions via combinatorial targeting of MAPK and PI3K/mTOR signaling pathways[J]. Oncotarget, 2017, 8(49):84697-84713.
[31] Breton Q, Plouhinec H, Prunier-Mirebeau D, et al. BRAF-V600E immunohistochemistry in a large series of glial and glial-neuronal tumors[J]. Brain Behav, 2017, 7(3):e00641.
[32] Kim W Y, Kim H, Hwang T S, et al. Comparison between real-time PCR and pyrosequencing for detection of BRAF V600E mutation in thyroid fine-needle aspirates[J]. Appl Immunohistochem Mol Morphol, 2017, 25(5):358-365.
[33] Bisschop C, Ter E A, Bosman L J, et al. Rapid BRAF mutation tests in patients with advanced melanoma:comparison of immunohistochemistry, Droplet Digital PCR, and the Idylla Mutation Platform[J]. Melanoma Res, 2018, 28(2):96-104.
[34] Ryall S, Arnoldo A, Krishnatry R, et al. Multiplex detection of pediatric low-grade glioma signature fusion transcripts and duplications using the NanoString nCounter system[J]. J Neuropathol Exp Neurol, 2017, 76(7):562-570.
[35] Tsang H F, Xue V W, Koh S P, et al. NanoString, a novel digital color-coded barcode technology:current and future applications in molecular diagnostics[J]. Expert Rev Mol Diagn, 2017, 17(1):95-103.